SecBot SecBot
Insider Cluster (5 insiders) ·Filed May 15, 2026

KPTI

Karyopharm Therapeutics Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago
Insider cluster: 5 insiders, $0.0M total
Actionable Insight • Neutral

The insider sales are too small to be informative. The real risk is the $400M shelf registration and going-concern warning, monitor for any ATM drawdown or equity offering in the coming weeks, which would be highly dilutive. The Q1 beat and reaffirmed guidance provide near-term support, but the cash crunch is the dominant factor.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$7.14
T+0 close · May 15, 2026 · via day close
Latest settled
−71.57%
T+60 · $2.03
Vs SPY
−76.42%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 18 $7.14entry
  2. T+1 · 6mo ago +4.62%α +5.27% · $7.47
  3. T+5 · 6mo ago +25.63%α +24.01% · $8.97
  4. T+20 · 5mo ago +27.45%α +25.87% · $9.10
  5. T+60 · 3mo ago −71.57%α −76.42% · $2.03

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Five Karyopharm insiders, including the CEO and C-suite, sold a total of $31K in open-market sales on May 14, 2026, the same day the company reported Q1 earnings. The sales are trivial relative to the $201M market cap (0.015%) and follow a pattern of stock grants on May 13, suggesting the sales are likely liquidity-driven to cover tax obligations or diversify, not a bearish signal. The cluster is amplified by the cross-filing context of a $400M shelf registration and going-concern warning, but the dollar amount is too small to be material.

Key Financial Metrics

Direction
selling
Total Value
$31.0K
Insiders
5

Key Facts

  • Five insiders sold a total of 3,254 shares for $31K on May 14, 2026, representing 0.015% of market cap.
  • CEO Richard Paulson sold the largest portion: 2,203 shares for $21K.
  • All five insiders received stock grants on May 13, 2026 (non-cash, $0 value), preceding the sales.
  • The sales occurred on the same day as Q1 2026 earnings release (revenue $35.1M, up 17% YoY; EPS beat consensus by 29%).
  • A $400M shelf registration (including $100M ATM) was filed 11 days prior, representing ~202% dilution risk.
  • The company has a going-concern warning with cash runway only into late Q3 2026.

Financial Impact

Total insider sales of $31K, or 0.015% of $201M market cap, immaterial.

dilutioncash runway

Risk Factors

  • Massive potential dilution from $400M shelf registration (202% of market cap).
  • Going-concern warning with cash runway only into late Q3 2026.
  • Phase 3 SENTRY myelofibrosis trial missed second co-primary endpoint.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-KPTI-1778875977454

US Market Status

Market Closed · Opens in 8h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 15, 2026